JPS6256411A - Beautifying agent - Google Patents
Beautifying agentInfo
- Publication number
- JPS6256411A JPS6256411A JP60196827A JP19682785A JPS6256411A JP S6256411 A JPS6256411 A JP S6256411A JP 60196827 A JP60196827 A JP 60196827A JP 19682785 A JP19682785 A JP 19682785A JP S6256411 A JPS6256411 A JP S6256411A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- salt
- phosphatidylethanolamine
- phase
- phosphatidylserine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 claims abstract description 20
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims abstract description 17
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000467 phytic acid Substances 0.000 claims abstract description 11
- 229940068041 phytic acid Drugs 0.000 claims abstract description 11
- 235000002949 phytic acid Nutrition 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims abstract description 10
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 9
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims abstract description 8
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 6
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000787 lecithin Substances 0.000 claims abstract description 6
- 235000010445 lecithin Nutrition 0.000 claims abstract description 6
- 229940067606 lecithin Drugs 0.000 claims abstract description 6
- 229960003951 masoprocol Drugs 0.000 claims abstract description 6
- 239000000473 propyl gallate Substances 0.000 claims abstract description 4
- 235000010388 propyl gallate Nutrition 0.000 claims abstract description 4
- 229940075579 propyl gallate Drugs 0.000 claims abstract description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 17
- 230000002087 whitening effect Effects 0.000 claims description 14
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 claims description 6
- 239000004318 erythorbic acid Substances 0.000 claims description 6
- 235000010350 erythorbic acid Nutrition 0.000 claims description 6
- 229940026239 isoascorbic acid Drugs 0.000 claims description 6
- 241000147041 Guaiacum officinale Species 0.000 claims description 3
- 229940091561 guaiac Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 8
- 239000007787 solid Substances 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract description 2
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 abstract 2
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 abstract 2
- 229920002907 Guar gum Polymers 0.000 abstract 1
- 239000000665 guar gum Substances 0.000 abstract 1
- 229960002154 guar gum Drugs 0.000 abstract 1
- 235000010417 guar gum Nutrition 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 23
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000003921 oil Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- -1 Polyoxyethylene Polymers 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000007854 depigmenting agent Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- ULBTUVJTXULMLP-UHFFFAOYSA-N butyl octadecanoate Chemical group CCCCCCCCCCCCCCCCCC(=O)OCCCC ULBTUVJTXULMLP-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は皮膚美白効果が著しく改良された安全性の高い
美白剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a highly safe whitening agent with significantly improved skin whitening effects.
[従来の技術]
皮膚のしみなどの発生機序については不明な点もあるが
、一般には、ホルモンの異常や日光からの紫外線の刺激
が原因となってメラニン色素が形成され、これが皮膚内
に異常沈着するものと考えられている。このようなじみ
やあざの治療法にはメラニンの生成を抑制する物質、例
えばビタミンCを大量に投与する方法、グルタチオン等
を注射する方法あるいはL−アスコルビン酸、システィ
ンなどを軟膏、クリーム、ローションなどの形態にして
、局所に塗布するなどの方法がとられている。また欧米
ではハイドロキノン製剤が医薬品として用いられている
。[Conventional technology] Although there are some points that are unclear about the mechanism by which skin spots occur, in general, melanin pigments are formed due to hormonal abnormalities or stimulation of ultraviolet rays from sunlight, and this is caused by the formation of melanin within the skin. It is thought that it is abnormally deposited. Treatments for such bruises include the administration of large amounts of substances that suppress melanin production, such as large doses of vitamin C, injections of glutathione, or the use of ointments, creams, and lotions containing L-ascorbic acid, cysteine, etc. Methods such as making it into a form and applying it locally are used. Additionally, hydroquinone preparations are used as pharmaceuticals in Europe and America.
[発明が解決しようとする問題点]
L−アスコルビン酸類は安定性の面で問題があり、水分
を含む系では不安定で変色、変臭の原因となり、グルタ
チオン、システィンなどのチオール系化合物はハイドロ
キノンを除いてはその効果の発現がきわめて緩慢である
ため、美白効果が十分ではない。一方、ハイドロキノン
は効果は一応認められているが、感作性があるため一般
には、使用が制限されている。そこでその安全性を向上
させるため高級脂肪酸のモノエステルなどにする試みが
なされているが、これらのエステルは体内の加水分解酵
素によって分解されるため必ずしも安全とは言いがたい
。[Problems to be solved by the invention] L-ascorbic acids have problems in terms of stability, and are unstable in systems containing water, causing discoloration and odor. With the exception of , the onset of the effect is extremely slow, so the whitening effect is not sufficient. On the other hand, although hydroquinone has been shown to be effective, its use is generally restricted due to its sensitizing properties. In order to improve its safety, attempts have been made to use monoesters of higher fatty acids, but these esters are not necessarily safe because they are degraded by hydrolytic enzymes in the body.
[問題点を解決するための手段]
このような事情に鑑み、本発明者等は、人体に好ましく
ない副作用を有ざずかつ優れた美白剤を開発すべく鋭意
研究を重ねた結果、
(1)セザモール
(2)レシチン
(3)フィチン酸
(4)フィチン酸の塩
(5)フォスファチジルエタノールアミン(6)フォス
ファチジルセリン
(7)エリソルビン酸
(8)エリソルビン酸の塩
(9)グアヤク脂
(10)ノルジヒドログアイアレチック酸(11)ノル
ジヒドログアイアレチック酸の塩(12)没食子酸プロ
ピル
がきわめて安全性に優れており、また安定性もよく、十
分に美白効果を発揮することを認め、本発明を完成する
に至った。[Means for Solving the Problems] In view of the above circumstances, the present inventors have conducted extensive research to develop an excellent skin whitening agent that does not have any unfavorable side effects on the human body, and have found (1) ) Sezamol (2) Lecithin (3) Phytic acid (4) Salt of phytic acid (5) Phosphatidylethanolamine (6) Phosphatidylserine (7) Erythorbic acid (8) Salt of Erythorbic acid (9) Guaiac butter (10) Nordihydroguaiaretic acid (11) Salt of nordihydroguaiaretic acid (12) Propyl gallate is extremely safe and stable, and has a sufficient whitening effect. This was recognized and the present invention was completed.
すなわち、本発明は有効成分として、上記化合物の1種
又は2種以上を含有することを特徴とする美白剤である
。That is, the present invention is a whitening agent characterized by containing one or more of the above compounds as active ingredients.
以下本発明の構成について述べる。The configuration of the present invention will be described below.
本発明で使用する化合物は
(1)セザモール
(2)レシチン
(3)フィチン酸
(4)フィチン酸の塩
(5)フォスファチジルエタノールアミン(6)フォス
ファチジルセリン
(7)エリソルビン酸
(8)エリソルビン酸の塩
(9)グアヤク脂
(10)ノルジヒドログアイアレチック酸(11)ノル
ジヒドログアイアレチック酸の塩(12)没食子酸プロ
ピル
であり、フィチン酸、エリソルビン酸、ノルジヒドログ
アイアレチック酸の塩としてはナトリウム塩やカリウム
塩などがあげられる。これらの化合物を美白剤に配合す
るには一般の脂溶性化合物を配合する方法にならえばよ
い。The compounds used in the present invention are (1) sezamol (2) lecithin (3) phytic acid (4) salts of phytic acid (5) phosphatidylethanolamine (6) phosphatidylserine (7) erythorbic acid (8) Erythorbic acid salt (9) Guaiac butter (10) Nordihydroguaiaretic acid (11) Nordihydroguaiaretic acid salt (12) Propyl gallate, phytic acid, erythorbic acid, nordihydroguaiaretic acid Salts include sodium salts and potassium salts. These compounds can be blended into a whitening agent by following the method of blending general fat-soluble compounds.
これらの化合物は、1種又は2種以上が適宜選択され配
合される。配合量は、所望の剤型に応じて適宜選択でき
るが、通常組成物全量に対して乾燥固形分として0.0
05〜15重量駕、好ましくは、0.1〜10重量%程
度である。0.005重量%未満では、効果が乏しくな
る傾向があり、逆に15重量%を越えて配合しても効果
の大きな増加は望めない。One or more of these compounds are appropriately selected and blended. The blending amount can be selected as appropriate depending on the desired dosage form, but it is usually 0.0% as a dry solid content based on the total amount of the composition.
The amount is about 0.05 to 15% by weight, preferably about 0.1 to 10% by weight. If it is less than 0.005% by weight, the effect tends to be poor, and conversely, if it is added in excess of 15% by weight, no significant increase in the effect can be expected.
本発明の美白剤は、乳化型、可溶化型、分散型、皮膜型
、石鹸、軟膏などの形態とすることができる。The whitening agent of the present invention can be in the form of an emulsion type, a solubilized type, a dispersion type, a film type, a soap, an ointment, and the like.
本発明の美白剤は、上記必須成分に加えて、必要に応じ
て油分、紫外線吸収剤、界面活性剤、防腐剤、保湿剤、
香料、水、アルコール、増粘剤、色剤等を適宜配合する
ことができる。In addition to the above-mentioned essential ingredients, the skin whitening agent of the present invention may optionally contain oil, ultraviolet absorbers, surfactants, preservatives, humectants,
Flavors, water, alcohol, thickeners, coloring agents, etc. can be added as appropriate.
[本発明の効果]
本発明の美白剤の美白効果を明らかにするために下記の
実験例を示す。[Effects of the present invention] In order to clarify the whitening effect of the whitening agent of the present invention, the following experimental examples are shown.
(実験例)
表1の処方に基づき常法によってローシコンを製造し美
白効果を測定した。(Experimental Example) Low Shicon was manufactured by a conventional method based on the formulation shown in Table 1, and its whitening effect was measured.
顔面に、しみ、そばかす等を有する年齢25〜42才の
女性110名をパネルとし、一群10名どし118¥に
わけ、各成分含有ローションを1日1回3ケ月間毎日顔
面に塗布させ、使用後の美白効果を下記の判定基準に基
づいて判定した。A panel of 110 women between the ages of 25 and 42 who had spots, freckles, etc. on their faces were divided into groups of 10 for 118 yen each, and each lotion containing each ingredient was applied to their faces once a day for 3 months. The whitening effect after use was evaluated based on the following criteria.
(判定基準) 著効:色素沈着が目立たなくなった。(Judgment criteria) Significant results: Pigmentation became less noticeable.
有効二色製沈着がかなり薄くなった。The effective two-color deposit became much thinner.
やや有効二色製沈着がやや薄くなった。Slightly effective two-color deposit became slightly thinner.
無効二色製沈着に変化がなかフた。There was no change in the two-color deposit.
(判定)
A:被験者のうち著効および有効の示す割合が80%以
上の場合
B:被験者のうち著効および有効の示す割合が50〜8
0%の場合
C:被験者のうち著効および有効の示す割合が50%以
下の場合
この結果を表1に示した。(Judgment) A: When the proportion of subjects showing excellent response and efficacy is 80% or more B: The proportion of subjects showing excellent response and efficacy is 50-8
0% case C: The proportion of subjects showing marked response and efficacy is 50% or less The results are shown in Table 1.
表1から明らかなように本発明の美白剤は、美白効果に
優れていることがわる。また皮膚刺激性、感作性は認め
られず、安全性もすぐれていることがわかった。As is clear from Table 1, the whitening agent of the present invention has an excellent whitening effect. Furthermore, no skin irritation or sensitization was observed, and it was found to be highly safe.
(以下余白)
[実施例]
次に実施例をあげて本発明をざらに詳しく説明する。本
発明はこれによって限定されるものではない。配合量は
重量%である。(The following is a blank space) [Example] Next, the present invention will be explained in detail with reference to Examples. The present invention is not limited thereby. The blending amount is in weight%.
実施例1 バニシングクリーム
ステアリン酸 5.0ス
テアリルアルコール 4.0ステ
アリン酸ブチルアルコールエステル 8.0グリセリ
ンモノステアリン酸エステル 2.0レシチン
1・0プロピレングリ
コール 10.0グリセリン
4.0苛性カリ
0,2防腐剤・酸化防止剤
適量香料
適量イオン交換水
残余(製法)
イオン交換水にプロピレングリコールと苛性カリを加え
溶解し加熱して700Cに保つ(水相)。他の成分を混
合し加熱融解して70℃に保つ(油相)。水相に油相を
徐々に加え、全部加え終わってからしばらくその温度に
保ち反応をおこさせる。その後ホモミキサーで均一に乳
化し、よくかきまぜなから30℃まで冷却する。Example 1 Vanishing cream Stearic acid 5.0 Stearyl alcohol 4.0 Stearic acid butyl alcohol ester 8.0 Glycerin monostearate 2.0 Lecithin
1.0 Propylene Glycol 10.0 Glycerin
4.0 caustic potash
0.2 preservatives/antioxidants
Appropriate amount of fragrance
Appropriate amount of ion exchange water
Residue (manufacturing method) Add propylene glycol and caustic potash to ion-exchanged water, dissolve, heat, and maintain at 700C (water phase). Mix other ingredients, heat and melt and keep at 70°C (oil phase). Gradually add the oil phase to the water phase, and after all addition is complete, maintain the temperature for a while to allow the reaction to occur. Then, emulsify the mixture uniformly using a homomixer, stir well, and cool to 30°C.
実施例2 中性クリーム
ステアリルアルコール 7.0ステアリ
ン酸 2.0水添ラノリン
2,0スクワラン
5.02−オクチルドデシルアルコール
6.0ポリオキシエチレン(25モル)
セチルアルコールエーテル 3.0グリセリンモノ
ステアリン酸エステル 2.0フオスフアチジルセリン
1.5プロピレングリコール
5.0香料 適量
防腐剤・酸化防止剤 適量イオン交換水
残余(製法)
イオン交換水にプロピレングリコールを加え加熱して7
0℃に保つ(水相)。他の成分を混合し加熱融解して7
0℃に保つ(油相)。水相に油相を加え予備乳化をおこ
ない、ホモミキサーで均一に乳化した後、よくかきまぜ
ながら30℃まで冷却する。Example 2 Neutral Cream Stearyl Alcohol 7.0 Stearic Acid 2.0 Hydrogenated Lanolin
2,0 squalane
5.02-Octyldodecyl alcohol
6.0 Polyoxyethylene (25 moles) Cetyl alcohol ether 3.0 Glycerin monostearate 2.0 Phosphatidylserine 1.5 Propylene glycol
5.0 Fragrance Appropriate amount Preservative/Antioxidant Appropriate amount Ion-exchanged water Remainder (manufacturing method) Add propylene glycol to ion-exchanged water and heat.7
Keep at 0°C (aqueous phase). Mix other ingredients and heat and melt 7.
Keep at 0°C (oil phase). The oil phase is pre-emulsified by adding the oil phase to the water phase, uniformly emulsified using a homomixer, and then cooled to 30°C while stirring well.
実施例3 コールドクリーム
固形パラフィン 5.0密ロウ
10.0ワセリン
15.0流動パラフイン
41.0グリセリンモノステアリン酸
エステル 2.0ポリオキシエチレン(20モル)
ソルビタンモノラウリン酸エステル 2.0フオスフア
チジルエタノールアミン 1.0石鹸粉末
0.1硼砂
0.2香料
適量防腐剤・酸化防止剤 適
量イオン交換水 残余(製法)
イオン交換水に石鹸粉末と硼砂を加え加熱溶解して70
℃に保つ(水相)。他の成分を混合し加熱融解して70
℃に保つ(油相)。水相に油相をかきまぜながら徐々に
加え反応を行う。反応終了後ホモミキサーで均一に乳化
し、乳化後よくかキヨせなから30℃まで冷却する。Example 3 Cold cream solid paraffin 5.0 Hitsuwa 10.0 Vaseline
15.0 Liquid paraffin
41.0 Glycerin monostearate 2.0 Polyoxyethylene (20 mol) Sorbitan monolaurate 2.0 Phosphatidylethanolamine 1.0 Soap powder
0.1 borax
0.2 fragrance
Appropriate amount of preservative/antioxidant Appropriate amount of ion-exchanged water Residue (manufacturing method) Add soap powder and borax to ion-exchanged water, heat and dissolve.
Keep at °C (aqueous phase). Mix the other ingredients and heat and melt for 70 minutes.
Keep at °C (oil phase). The oil phase is gradually added to the water phase while stirring to carry out the reaction. After the reaction is completed, the mixture is uniformly emulsified using a homomixer, and after the emulsification is cooled to 30°C.
実施例4 乳液
ステアリン酸 2.5セチルア
ルコール 1.5ワセリン
5.0流動パラフイン
10.0ポリオキシエチレン(10モル
)
モノオレイン酸エステル 2.0ポリエチレ
ングリコール1500 3.0トリエタノー
ルアミン 1.0フイチン酸
0.5フォスファチジルエタノー
ルアミン 1.0香料
適量防腐剤・酸化防止剤 適量
イオン交換水 残余(製法)
イオン交換水にポリエチレングリコール1500とトリ
エタノールアミンを加え加熱溶解して70℃に保つ(水
相)。他の成分を混合し加熱融解して70℃に保つ(油
相)。水相に油相を加え予備乳化を行いホモミキサーで
均一に乳化し、乳化後よくかきまぜながら30℃まで冷
却する。Example 4 Emulsion Stearic acid 2.5 Cetyl alcohol 1.5 Vaseline
5.0 liquid paraffin
10.0 Polyoxyethylene (10 mol) Monooleic acid ester 2.0 Polyethylene glycol 1500 3.0 Triethanolamine 1.0 Phytic acid
0.5 Phosphatidylethanolamine 1.0 Fragrance
Appropriate amount of preservative/antioxidant Appropriate amount of ion-exchanged water Remaining (manufacturing method) Add polyethylene glycol 1500 and triethanolamine to ion-exchanged water, dissolve by heating, and keep at 70°C (water phase). Mix other ingredients, heat and melt and keep at 70°C (oil phase). The oil phase is pre-emulsified by adding the oil phase to the water phase, and the mixture is uniformly emulsified using a homomixer. After emulsification, the mixture is cooled to 30°C while stirring well.
実施例5 乳液
マイクロクリスタリンワックス 1.0密ロウ
2.0ラノリン
20.0流動パラフイン
10.0スクワラン
5.0ソルビタンセスキオレイン酸エステル
4.0ポリオキシエチレン(20モル)
ソルビタンモノオレイン酸エステル 1.0フイチン酸
3.0プロピレングリコー
ル 7.0香料
適量防腐剤・酸化防止剤
適量イオン交換水 残余(製
法)
イオン交換水にプロピレングリコールを加え加熱して7
0℃に保つ(水相)。他の成分を混合し加熱溶解して7
0℃に保つ(油相)。油相をかきまぜながら、これに水
相を徐々に加え、ホモミキサーで均一に乳化する。乳化
後よくかきまぜながら30℃まで冷却する。Example 5 Emulsion Microcrystalline Wax 1.0 Mitsuwax
2.0 lanolin
20.0 liquid paraffin
10.0 Squalane
5.0 Sorbitan sesquioleate 4.0 Polyoxyethylene (20 mol) Sorbitan monooleate 1.0 Phytic acid 3.0 Propylene glycol 7.0 Fragrance
Appropriate amount of preservatives and antioxidants
Appropriate amount of ion-exchanged water Remaining (manufacturing method) Add propylene glycol to ion-exchanged water and heat.
Keep at 0°C (aqueous phase). Mix other ingredients and heat to dissolve 7.
Keep at 0°C (oil phase). While stirring the oil phase, gradually add the water phase to it and uniformly emulsify with a homomixer. After emulsification, cool to 30°C while stirring well.
実施例6 化粧水
(アルコール相)
95%エチルアルコール 10.0ポ
リオキシエチレン(60モル)
硬化ヒマシ油 2.0
プロピレングリコール 4.0オレイル
アルコール 0.ルシチン
2・5(水相)
グリセリン 5.0紫外線吸収
剤 適量イオン交換水
残余(製法)
水相、アルコール相を調整後可溶化する。Example 6 Lotion (alcohol phase) 95% ethyl alcohol 10.0 Polyoxyethylene (60 mol) Hydrogenated castor oil 2.0 Propylene glycol 4.0 Oleyl alcohol 0. Lucitin
2.5 (Aqueous phase) Glycerin 5.0 Ultraviolet absorber Appropriate amount of ion-exchanged water
Residue (manufacturing method) Solubilize after adjusting the aqueous phase and alcohol phase.
実施例7 ビールオフ型パック
(アルコール相)
95χエタノール 10.0ポ
リオキシエチレン(15モル)
オレイルアルコールエーテル 2.0セザモー
ル 5・0防腐剤
適量香料
適量(水相)
ポリビニルアルコール 12.0グリセ
リン 3.0ポリエチレング
リコール1500 1.0イオン交換水
残余(製法)
80℃にて水相を調整し、50℃に冷却する。ついで室
温で調整したアルコール相を添加後均−に混合し、放冷
する。Example 7 Beer-off type pack (alcohol phase) 95χ ethanol 10.0 Polyoxyethylene (15 mol) Oleyl alcohol ether 2.0 Sezamol 5.0 Preservative
Appropriate amount of fragrance
Appropriate amount (aqueous phase) Polyvinyl alcohol 12.0 Glycerin 3.0 Polyethylene glycol 1500 1.0 Ion exchange water
Residue (manufacturing method) Adjust the aqueous phase at 80°C and cool to 50°C. After adding the alcohol phase prepared at room temperature, the mixture is evenly mixed and allowed to cool.
Claims (1)
とを特徴とする美白剤。 (1)セザモール (2)レシチン (3)フィチン酸 (4)フィチン酸の塩 (5)フォスファチジルエタノールアミン (6)フォスファチジルセリン (7)エリソルビン酸 (8)エリソルビン酸の塩 (9)グアヤク脂 (10)ノルジヒドログアイアレチック酸 (11)ノルジヒドログアイアレチック酸の塩 (12)没食子酸プロピル[Scope of Claims] A whitening agent characterized by containing one or more selected from the following compounds. (1) Sezamol (2) Lecithin (3) Phytic acid (4) Salt of phytic acid (5) Phosphatidylethanolamine (6) Phosphatidylserine (7) Erythorbic acid (8) Salt of Erythorbic acid (9) Guaiac fat (10) Nordihydroguaiaretic acid (11) Salt of nordihydroguaiaretic acid (12) Propyl gallate
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60196827A JPS6256411A (en) | 1985-09-05 | 1985-09-05 | Beautifying agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60196827A JPS6256411A (en) | 1985-09-05 | 1985-09-05 | Beautifying agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6256411A true JPS6256411A (en) | 1987-03-12 |
Family
ID=16364321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60196827A Pending JPS6256411A (en) | 1985-09-05 | 1985-09-05 | Beautifying agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6256411A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5956033A (en) * | 1982-09-21 | 1984-03-31 | Matsushita Electric Ind Co Ltd | Air conditioner capacity control method |
| WO1995005156A1 (en) * | 1993-08-17 | 1995-02-23 | Schering-Plough Healthcare Products, Inc. | Compositions for treating corns, calluses and warts |
| EP0650720A1 (en) * | 1993-10-28 | 1995-05-03 | Sanwa Kagaku Kenkyusho Co., Ltd. | Skin care and deodorant compositions |
| EP0841058A3 (en) * | 1996-11-06 | 1999-09-01 | Rhone-Poulenc Rorer Gmbh | Phospholipid composition, method of making it and its use |
| US6278004B1 (en) | 1996-11-06 | 2001-08-21 | Aventis Pharma Deutschland Gmbh | Stabilized phospholipidic composition |
| US6368995B1 (en) | 1998-09-09 | 2002-04-09 | Maruzen Petrochemical Co., Ltd. | Solid catalysts for the polymerization of olefins and process for the production of olefin polymers therewith |
| JP2005272444A (en) * | 2004-02-25 | 2005-10-06 | Kose Corp | Topical skin preparation |
| EP1648399A4 (en) * | 2003-07-22 | 2008-03-05 | Marta Rendon | Method and topical composition for the treatment of hyperpigmented skin |
-
1985
- 1985-09-05 JP JP60196827A patent/JPS6256411A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5956033A (en) * | 1982-09-21 | 1984-03-31 | Matsushita Electric Ind Co Ltd | Air conditioner capacity control method |
| WO1995005156A1 (en) * | 1993-08-17 | 1995-02-23 | Schering-Plough Healthcare Products, Inc. | Compositions for treating corns, calluses and warts |
| EP0650720A1 (en) * | 1993-10-28 | 1995-05-03 | Sanwa Kagaku Kenkyusho Co., Ltd. | Skin care and deodorant compositions |
| EP0841058A3 (en) * | 1996-11-06 | 1999-09-01 | Rhone-Poulenc Rorer Gmbh | Phospholipid composition, method of making it and its use |
| US6100413A (en) * | 1996-11-06 | 2000-08-08 | Rhone-Poulenc Rorer Gmbh & Co. | Method for the stabilization of a phospholipidic composition, method for the production of such a stabilized composition and its use |
| US6278004B1 (en) | 1996-11-06 | 2001-08-21 | Aventis Pharma Deutschland Gmbh | Stabilized phospholipidic composition |
| US6368995B1 (en) | 1998-09-09 | 2002-04-09 | Maruzen Petrochemical Co., Ltd. | Solid catalysts for the polymerization of olefins and process for the production of olefin polymers therewith |
| EP1648399A4 (en) * | 2003-07-22 | 2008-03-05 | Marta Rendon | Method and topical composition for the treatment of hyperpigmented skin |
| JP2005272444A (en) * | 2004-02-25 | 2005-10-06 | Kose Corp | Topical skin preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0899820A (en) | Skin external agent | |
| JPH08133952A (en) | Skin preparation for external use | |
| JPS6256411A (en) | Beautifying agent | |
| JPS6245527A (en) | Preventive and remedy for gray hair | |
| KR101460777B1 (en) | Cosmetic composition for improving acne | |
| JP2578394B2 (en) | Whitening agent | |
| JPH0745387B2 (en) | Hair growth and hair growth promoter | |
| JPS6360910A (en) | Skin drug for external use | |
| JP2676049B2 (en) | Skin cosmetics | |
| JPH08133948A (en) | Skin preparation for external use | |
| JP2663136B2 (en) | Whitening cosmetics | |
| JPH08133950A (en) | Skin preparation for external use | |
| JPS6210006A (en) | Skin cosmetic | |
| EP0717985B1 (en) | Dermatologic preparation | |
| JPS6322510A (en) | External preparation for skin | |
| JPH07149622A (en) | Beautifying and whitening preparation | |
| JPH0692833A (en) | Skin external agent | |
| JPH08133949A (en) | Skin preparation for external use | |
| JPS6127367B2 (en) | ||
| JP2522803B2 (en) | Cosmetics | |
| JPH08133954A (en) | Skin preparation for external use | |
| JPS60116616A (en) | Cosmetic | |
| JPH0648929A (en) | Skin external preparation | |
| JP3615557B2 (en) | Anti-pigmentation agent | |
| JPH0788294B2 (en) | Cosmetics |